Skip to main content Skip to main navigation menu Skip to site footer
MedNext Journal of Medical and Health Sciences
Review
DOI: 10.54448/mdnt23S14
Submitted: 20-01-2023
Published: 20-01-2023

Major aspects of the use of bisphosphonates for dental implants in patients with or without osteoporosis:: a systematic review of clinical studies

UNORTE - University Center of Northern São Paulo, Dentistry department, São José do Rio Preto, São Paulo, Brazil / UNIPOS - Post graduate and continuing education, Dentistry department, São José do Rio Preto, São Paulo, Brazil
UNORTE - University Center of Northern São Paulo, Dentistry department, São José do Rio Preto, São Paulo, Brazil / UNIPOS - Post graduate and continuing education, Dentistry department, São José do Rio Preto, São Paulo, Brazil
UNORTE - University Center of Northern São Paulo, Dentistry department, São José do Rio Preto, São Paulo, Brazil / UNIPOS - Post graduate and continuing education, Dentistry department, São José do Rio Preto, São Paulo, Brazil
UNORTE - University Center of Northern São Paulo, Dentistry department, São José do Rio Preto, São Paulo, Brazil / UNIPOS - Post graduate and continuing education, Dentistry department, São José do Rio Preto, São Paulo, Brazil
UNORTE - University Center of Northern São Paulo, Dentistry department, São José do Rio Preto, São Paulo, Brazil / UNIPOS - Post graduate and continuing education, Dentistry department, São José do Rio Preto, São Paulo, Brazil
UNORTE - University Center of Northern São Paulo, Dentistry department, São José do Rio Preto, São Paulo, Brazil / UNIPOS - Post graduate and continuing education, Dentistry department, São José do Rio Preto, São Paulo, Brazil
Bisphosphonates Osteonecrosis Osteoporosis Dental implant Complications

Abstract

Introduction: In the setting of Medication-Related Osteonecrosis of the Jaw (MRONJ) it was first reported in association with the use of bisphosphonates (BP) by maxillofacial surgeons. The potency and route of administration of BPs are identified as important risk factors. Objective: It was to evaluate the use of bisphosphonates and their side effects in patients with or without osteoporosis, with emphasis on osteonecrosis of the jaws, for dental implants. Methods: The systematic review rules of the PRISMA Platform were followed. The search was carried out from October to December 2022 in the Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases, using articles from 2005 to 2022. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed accordingly. according to the Cochrane instrument. Results and Conclusion: A total of 120 articles were found, and 55 articles were evaluated in full and 34 were included and developed in this systematic review study. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 15 studies with a high risk of bias and 32 studies that did not meet GRADE. For patients with established osteoporosis, there are drugs that, in general, act directly on the bone remodeling process, seeking to reduce bone resorption, including BP, which are drugs of proven efficacy that act in the prevention and treatment of several bone diseases. Osteoporosis is a factor that delays the regeneration of the maxillary bone in patients submitted to implant surgery, prolonging the normal recovery time of the maxillary bone, which can vary from three to six months. Alendronate sodium is used to decrease bone resorption, the drug should be considered an adjuvant therapeutic agent for the treatment of osteoporosis. However, studies have shown that there is a risk of osteonecrosis with the use of bisphosphonates.

Metrics

Metrics Loading ...

References

  1. Miranda-Silva W, Montezuma MA, Benites BM, Bruno JS, Fonseca FP, Fregnani ER. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support Care Cancer. 2020 Nov;28(11):5397-5404. doi: 10.1007/s00520-020-05374-4.
  2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72(10):1938-1956.
  3. Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev 2015;41(5):455-464.
  4. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrota B. American association of oral and maxillofacial surgeons position paper on biphosphonate-
  5. MedNEXT J Med Health Sci (2023) Page 7 of 8
  6. Vol 4 Suppl 1 Year
  7. MedNEXT Journal of Medical and Health
  8. Sciences
  9. related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67(5suppl): 212.
  10. Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 2009;14(11):1154-1166.
  11. Steel BJ. Management of Medication-related Osteonecrosis of the Jaw (MRONJ) risk in patients due to commence anti-resorptive/anti-angiogenic drugs - how should predrug-treatment dental preventive care be organised? Community Dent Health. 2019 Nov 28;36(4):244-254. doi: 10.1922/CDH_4582Steel11.
  12. Anesi A, Generali L, Sandoni L, Pozzi S, Grande A. From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights. Int J Mol Sci. 2019 Oct 4;20(19):4925. doi: 10.3390/ijms20194925.
  13. Raj DV, Abuzar M, Borromeo GL. Bisphosphonates, healthcare professionals and oral health. Gerodontology. 2016 Mar;33(1):135-43. doi: 10.1111/ger.12141.
  14. Senturk MF, Cimen E, Tuzuner Oncul AM, Cambazoglu M. Oncologists awareness about bisphosphonate related osteonecrosis of the jaws. J Pak Med Assoc. 2016 Jul;66(7):880-3.
  15. Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians' awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J. 2011 Aug;32(8):830-
  16. El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Support Care Cancer. 2015 Sep;23(9):2825-31. doi: 10.1007/s00520-015-2649-1.
  17. Lau J, Ng L, Siddiqi A, Zafar S. Paediatric Dentists Treating Children on Bisphosphonates: A Cross-Sectional Questionnaire-Based Study. Pediatr Dent. 2019 Jul 15;41(4):285-292.
  18. Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonaterelated osteonecrosis of the jaw. BMC Oral Health. 2016 Sep 7;16(1):92. doi: 10.1186/s12903-016-0290-0.
  19. Liede A, Amelio J, Bennett J, Goodman H, Peters PM, Barber R, Kehler E, Michael Sprafka J. Measuring and Improving Physician Knowledge of Safety Risks Using Traditional and Online Methods in Pharmacovigilance. Pharmaceut Med. 2017;31(4):257-266. doi: 10.1007/s40290-017-0196-4.
  20. Franchi S, Brucoli M, Boffano P, Dosio C, Benech A. Medical students' knowledge of medication related osteonecrosis of the jaw. J Stomatol Oral Maxillofac Surg. 2020 Sep;121(4):344-346. doi: 10.1016/j.jormas.2019.10.005. Epub 2019 Oct 28. PMID: 31672685.
  21. Hammarfjord O, Stassen LF. Bisphosphonate therapy and ankylosis of the temporomandibular joint: is there a relationship? A case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Sep;118(3):e68-70. doi: 10.1016/j.oooo.2014.02.011. Epub 2014 Feb 22. PMID: 24906945.
  22. Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S. Awareness and education of patients receiving bisphosphonates. J Craniomaxillofac Surg. 2012 Apr;40(3):277-82. doi: 10.1016/j.jcms.2011.04.011. Epub 2011 May 25. PMID: 21612939.
  23. Otto S, Schnoedt EM, Troeltzsch M, Kaeppler G, Aljohani S, Liebermann A, Fliefel R. Clinical and Radiographic Outcomes of Dental Implants in Patients treated with Antiresorptive Drugs: A Consecutive Case Series. J Oral Implantol. 2022 Apr 21. doi:
  24. 1563/aaid-joi-D-21-00035.
  25. Fiorillo L, Cicciù M, Tözüm TF, D'Amico C, Oteri G, Cervino G. Impact of bisphosphonate drugs on dental implant healing and peri-implant hard and soft tissues: a systematic review. BMC Oral Health. 2022 Jul 17;22(1):291. doi: 10.1186/s12903022-02330-y.
  26. Sher J, Kirkham-Ali K, Luo JD, Miller C, Sharma D. Dental Implant Placement in Patients With a History of Medications Related to Osteonecrosis of the Jaws: A Systematic Review. J Oral Implantol. 2021 Jun 1;47(3):249-268. doi: 10.1563/aaid-joiD-19-00351.
  27. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin Oral Implants Res. 2018 Oct;29 Suppl 18:54-92. doi: 10.1111/clr.13282.
  28. Ourique SAM, Ito AY, Suarez OF. Osteoporose em Implantodontia: O Estado Atual da Questão. Rev. Bras. Implantodontia e Prótese sobre Implantes, 2005: 12(47/48): 23745.
  29. Goiato MC, Santos DM, Rondon BCS, Moreno A, Baptista GT, Verri FR et al. Care Required When Using Bisphosphonates in Dental Surgical Practice. J. craniofac. surg. 2010; 21(6):1966-70.
  30. Chadha GK, Ahmadieh A, Kumar S, Sedghizaded PP. Osseointegration of dental osteonecrosis of the jaw in patients treated with bisphosphonates therapy: a systematic review. J. oral implantol. 2013;39(4):510-20.
  31. Mellado-Valero A, Ferrer-García JC, CalvoCatalá J, Labaig- Rueda C. Implant treatment in patients with osteoporosis. Med. oral patol. oral cir. bucal. 2010; 15:52-7.
  32. López-Cedrún JL, Sanromán JF, García A, Peñarrocha M, Feijoo JF, Limeres J, Diz P. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series. Br. j. oral maxillofac. surg. 2012;51(8):874-9.
  33. Kwon T-G, Lee C-O, Park J-W, Choi S-Y, Rijal G, Shin H-I. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin. oral implants res. 2012; 00:1- 9.
  34. Yip JK, Borrell LN, Cho SC, Francisco H, Tarnow DP. Association between oral bisphosphonate use and dental implant failure among middleaged women. J. clin. periodontol. 2012;39:408- 14.
  35. Memon S, Weltman RL, Katancik JA. Oral Bisphosphonates: Early Endosseous Dental Implant Success and Crestal Bone Changes. A Retrospective Study. Int. j. oral maxillofac. implants. 2012;279(5):1216-22.
  36. Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50(5):1148- 51.
  37. MedNEXT J Med Health Sci (2023) Page 8 of 8
  38. Vol 4 Suppl 1 Year
  39. MedNEXT Journal of Medical and Health
  40. Sciences
  41. Jacobsen C, Metzler P, Rossle M, Obwegeser J, Zemann W, Gratz KW. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin. oral investig. 2013;17:167-75.
  42. Young L, Brown T, Lamont TJ. A comparison of techniques for the explantation of osseointegrated dental implants. Evid Based Dent. 2020 Dec;21(4):126-127. doi: 10.1038/s41432-020-0133-3. PMID: 33339970.
  43. Touyz LZG, Afrashtehfar KI. Implications of bisphosphonate calcium ion depletion interfering with desmosome epithelial seal in osseointegrated implants and pressure ulcers. Med Hypotheses. 2017 Sep;107:22-25. doi: 10.1016/j.mehy.2017.07.013. Epub 2017 Jul 18.
  44. Pogrel MA, Ruggiero SL. Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series. Int J Oral Maxillofac Surg. 2018 Feb;47(2):220-222. doi: 10.1016/j.ijom.2017.07.012. Epub 2017 Aug 10.

How to Cite

Antônio Munhoz, F. ., Alarcon Idalgo, F. ., Antonio dos Santos Pereira, S. ., Gomes Nunes, A. ., Naim Kassis, E. ., & José Cicareli, A. . (2023). Major aspects of the use of bisphosphonates for dental implants in patients with or without osteoporosis:: a systematic review of clinical studies. MedNEXT Journal of Medical and Health Sciences, 4(S1). https://doi.org/10.54448/mdnt23S14